Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 211

Similar articles for PubMed (Select 23788270)

1.

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.

Boxerman JL, Zhang Z, Safriel Y, Larvie M, Snyder BS, Jain R, Chi TL, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):945-54. doi: 10.1093/neuonc/not049. Epub 2013 Jun 19.

2.

Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.

Ratai EM, Zhang Z, Snyder BS, Boxerman JL, Safriel Y, McKinstry RC, Bokstein F, Gilbert MR, Sorensen AG, Barboriak DP.

Neuro Oncol. 2013 Jul;15(7):936-44. doi: 10.1093/neuonc/not044. Epub 2013 May 3.

3.

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.

Gállego Pérez-Larraya J, Lahutte M, Petrirena G, Reyes-Botero G, González-Aguilar A, Houillier C, Guillevin R, Sanson M, Hoang-Xuan K, Delattre JY.

Neuro Oncol. 2012 May;14(5):667-73. doi: 10.1093/neuonc/nos070. Epub 2012 Apr 4.

4.

FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.

Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, Landwehr C, Mack F, Schäfer N, Stuplich M, Kebir S, Vilz B, Scheffler B, Boström J, Simon M, Urbach H, Glas M, Herrlinger U.

Oncology. 2013;85(3):191-5. doi: 10.1159/000354692. Epub 2013 Sep 5.

PMID:
24008924
5.

Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.

Huang RY, Rahman R, Hamdan A, Kane C, Chen C, Norden AD, Reardon DA, Mukundun S, Wen PY.

Cancer. 2013 Oct 1;119(19):3479-88. doi: 10.1002/cncr.28210. Epub 2013 Jul 2.

6.

Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF.

Radiology. 2014 Apr;271(1):200-10. doi: 10.1148/radiol.13131305. Epub 2013 Nov 27.

7.

A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.

Møller S, Grunnet K, Hansen S, Schultz H, Holmberg M, Sorensen M, Poulsen HS, Lassen U.

Acta Oncol. 2012 Jul;51(6):797-804. doi: 10.3109/0284186X.2012.681063. Epub 2012 May 1.

PMID:
22548369
8.

Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab.

Thompson EM, Dosa E, Kraemer DF, Neuwelt EA.

J Neurooncol. 2011 Jun;103(2):353-60. doi: 10.1007/s11060-010-0397-0. Epub 2010 Sep 17.

PMID:
20848300
9.

Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

Brandes AA, Tosoni A, Basso U, Reni M, Valduga F, Monfardini S, Amistà P, Nicolardi L, Sotti G, Ermani M.

J Clin Oncol. 2004 Dec 1;22(23):4779-86. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

10.

Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial.

Hasselbalch B, Lassen U, Hansen S, Holmberg M, Sørensen M, Kosteljanetz M, Broholm H, Stockhausen MT, Poulsen HS.

Neuro Oncol. 2010 May;12(5):508-16. doi: 10.1093/neuonc/nop063. Epub 2010 Feb 5.

11.

Bevacizumab and daily temozolomide for recurrent glioblastoma.

Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, Peters KB, Friedman HS, Vredenburgh JJ.

Cancer. 2012 Mar 1;118(5):1302-12. doi: 10.1002/cncr.26381. Epub 2011 Jul 26.

12.

Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.

Lassen U, Sorensen M, Gaziel TB, Hasselbalch B, Poulsen HS.

Anticancer Res. 2013 Apr;33(4):1657-60.

PMID:
23564811
13.

Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.

Reardon DA, Desjardins A, Peters KB, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Bulusu A, Threatt S, Friedman AH, Vredenburgh JJ, Friedman HS.

J Neurooncol. 2012 Mar;107(1):155-64. doi: 10.1007/s11060-011-0722-2. Epub 2011 Oct 11.

14.

Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.

Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, Bertolini F, Finocchiaro G, Eoli M.

PLoS One. 2013 Sep 12;8(9):e74345. doi: 10.1371/journal.pone.0074345. eCollection 2013.

15.

Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).

Gil MJ, de Las Peñas R, Reynés G, Balañá C, Peréz-Segura P, García-Velasco A, Mesia C, Gallego O, Fernández-Chacón C, Martínez-García M, Herrero A, Andrés R, Benavides M, Quintanar T, Pérez-Martin X.

Anticancer Drugs. 2012 Jul;23(6):659-65. doi: 10.1097/CAD.0b013e3283534d3e.

PMID:
22634799
16.

Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.

Reardon DA, Desjardins A, Peters KB, Vredenburgh JJ, Gururangan S, Sampson JH, McLendon RE, Herndon JE 2nd, Coan A, Threatt S, Friedman AH, Friedman HS.

Cancer. 2011 Dec 1;117(23):5351-8. doi: 10.1002/cncr.26188. Epub 2011 May 16.

17.

MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.

Pichler J, Pachinger C, Pelz M, Kleiser R.

Eur J Radiol. 2013 May;82(5):e240-5. doi: 10.1016/j.ejrad.2012.12.018. Epub 2013 Feb 9.

PMID:
23399039
18.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA.

J Clin Oncol. 2009 Feb 10;27(5):740-5. doi: 10.1200/JCO.2008.16.3055. Epub 2008 Dec 29.

19.

Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.

Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB.

Neuro Oncol. 2011 Oct;13(10):1151-61. doi: 10.1093/neuonc/nor079. Epub 2011 Aug 19.

20.

Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.

LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM.

Neuro Oncol. 2013 Apr;15(4):442-50. doi: 10.1093/neuonc/nos323. Epub 2013 Feb 3.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk